Código QR (código de barras bidimensional)

Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy

Abstract Background The Janus kinase (JAK)1/JAK2 inhibitor baricitinib in combination with topical corticosteroids (TCS) improved moderate‐to‐severe atopic dermatitis (AD) in the phase 3 BREEZE‐AD7 trial. Patients with previous systemic therapy may have more severe, treatment‐resistant disease. Obje...

Fuld beskrivelse

Na minha lista:
Principais autores: Antonio Costanzo, Akio Tanaka, Tiago Torres, Bibiana Pérez‐García, Angelina Sontag, Yun‐Fei Chen, Fan Emily Yang, Jill Kolodsick, Hitoe Torisu‐Itakura, Najwa Somani
Format: Artigo
Sprog:Inglês
Udgivet: Wiley 2023-09-01
Serier:JEADV Clinical Practice
Fag:
atopic dermatitis
baricitinib
systemic therapy
Online adgang:https://doi.org/10.1002/jvc2.187
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker